Vidal L, et al. - Researchers performed a systematic review and meta-analysis of 9 randomized controlled trials (2726 patients) to examine the efficacy of bendamustine in patients with indolent B-cell lymphoid neoplasms, including chronic lymphocytic leukaemia (CLL). They also performed comparison of bendamustine with fludarabine-containing regimens, CVP (cyclophosphamide, vincristine, prednisolone), CHOP (CVP+ doxorubicin) and chlorambucil. Bendamustine treatment was correlated with reduced risk of neutropenia compared to other chemotherapy. For patients with indolent lymphoma, and CLL, bendamustine induction seems to be an efficacious option. After bendamustine induction, no evaluation of maintenance therapy was done, and potentially there is an interaction between the two. For patients with CLL, chemotherapy-free approach was identified as efficacious. However, toxicity related to this approach is not negligible